Fate Therapeutics, Inc. (FATE)

NASDAQ: FATE · Real-Time Price · USD

1.480

-0.080 (-5.13%)

At close: Feb 27, 2026, 4:00 PM EST

1.490

+0.010 (0.68%)

After-hours: Feb 27, 2026, 6:53 PM EST

Fate Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	6.65	13.63	63.53	96.3	55.85
Revenue Growth (YoY)	-51.24%	-78.55%	-34.03%	72.44%	77.66%
Cost of Revenue	-	118.53	157.19	320.45	215.52
Gross Profit	6.65	-104.9	-93.65	-224.15	-159.67
Selling, General & Admin	46.52	90.64	96.86	84.23	57.32
Research & Development	107.83	-	-	-	-
Operating Expenses	154.35	90.64	96.86	84.23	57.32
Operating Income	-147.7	-195.54	-190.51	-308.39	-216.99
Interest & Investment Income	11.05	17.29	17.19	5.84	1.31
Other Non Operating Income (Expenses)	0.34	6.73	7.3	20.32	3.53
EBT Excluding Unusual Items	-136.32	-171.53	-166.03	-282.22	-212.15
Asset Writedown	-	-14.74	-	-	-
Other Unusual Items	-	-	5.1	0.5	-
Pretax Income	-136.32	-186.26	-160.93	-281.72	-212.15
Net Income	-136.32	-186.26	-160.93	-281.72	-212.15
Net Income to Common	-136.32	-186.26	-160.93	-281.72	-212.15
Shares Outstanding (Basic)	119	114	98	97	95
Shares Outstanding (Diluted)	119	114	98	97	95
Shares Change (YoY)	4.49%	15.52%	1.64%	2.19%	15.00%
EPS (Basic)	-1.15	-1.64	-1.64	-2.91	-2.24
EPS (Diluted)	-1.15	-1.64	-1.64	-2.91	-2.24
Free Cash Flow	-112.04	-123.6	-138.42	-283.77	-213.57
Free Cash Flow Per Share	-0.94	-1.09	-1.41	-2.93	-2.25
Gross Margin	100.00%	-	-147.41%	-232.77%	-285.92%
Operating Margin	-2222.45%	-1434.52%	-299.86%	-320.24%	-388.56%
Profit Margin	-2051.08%	-1366.46%	-253.30%	-292.55%	-379.89%
Free Cash Flow Margin	-1685.78%	-906.79%	-217.87%	-294.68%	-382.43%
EBITDA	-134.8	-176.58	-172.23	-294.63	-211.14
EBITDA Margin	-	-	-271.09%	-	-
D&A For EBITDA	12.9	18.96	18.28	13.76	5.85
EBIT	-147.7	-195.54	-190.51	-308.39	-216.99
EBIT Margin	-	-	-299.86%	-	-

Updated Feb 26, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q